Company / Free Cash Flow
OCULAR THERAPEUTIX, INC Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$216.9M
FY2025
5-year range
-$216.9M / -$54.4M
FY2021-FY2025
Trend
-59.5%
vs FY2024
Sector context
#154 of 194
Health Care
What the data says
OCULAR THERAPEUTIX, INC's free cash flow of -$217M is lower than 79% of companies in the Health Care sector (FY2025). Free Cash Flow has declined for 3 consecutive years, from -$54M in FY2022 to -$217M in FY2025.
Based on SEC 10-K filings.
-$217M in FY2025.
Declined from -$76M to -$217M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 194This company -$216.9M Sector average $470.8M
▼
-146.1% below sector average
Key checks
Key Insights
- OCULAR THERAPEUTIX, INC's free cash flow has declined for 3 consecutive years.
- In FY2025, free cash flow decreased 59.5% year-over-year.
- Ranks #154 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$216.9M | -59.5% |
| FY2024 | -$136.0M | -78.1% |
| FY2023 | -$76.3M | -40.3% |
| FY2022 | -$54.4M | +31.8% |
| FY2021 | -$79.8M | +0.0% |
| FY2020 | -$79.8M | -35.9% |
| FY2019 | -$58.7M | -14.9% |
| FY2018 | -$51.1M | +13.0% |
| FY2017 | -$58.7M | -63.5% |
| FY2016 | -$35.9M | -175.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026